The controlled trial includes 550 patients worldwide and it aims to investigate reherniation, reoperation, economic impact and risk-factors associated with clinical outcomes following lumbar discectomy.
“This randomized trial is a massive undertaking and has already contributed significantly in confirming an elevated risk of reoperation in a subset of discectomy patients,” said Steven Garfin, MD, chairman of orthopedic surgery at University of California San Diego.
Intrinsic Therapeutics is a medical device company focused on treating lumbar disc herniations.
More articles on devices:
6 points on FDA panel physicians …and their payments from device companies
What is Stryker responsible for in the OtisMed settlement? 5 things to know
What happens when data links device company payments with physician decisions?
